NMT Logo
    • About NMT Medical
      • Who we are
      • Our History
      • Our Executive Team
      • Careers
        • Career Opportunities
        • Application for Employment
    • Structural Heart Repair
      • Patent Foramen Ovale
      • Atrial Septal Defect
      • Ventricular Septal Defect
      • FDA Disclaimer
    • NMT Technology
      • Technology Overview
      • Clinical History
      • BioSTAR®
        • Clinical Trials
        • Technology-Approach
      • STARFlex®
        • Clinical Trials
        • Technology Approach
      • CardioSEAL®
        • Technology Approach
    • Patient Education
      • Signs of Stroke
      • 10 Questions to ask your Doctor
      • Patient Guides
        • spanish patient guide
    • Medical Professional
      • Downloadable Documents
      • Conference Calendar
    • Investors
      • Corporate Profile
      • Stock Information
        • Historic Prices
      • Press Releases
      • Event Calendar
      • Archived Webcasts
      • Presentations
      • Corporate Governance
        • Officers & Directors
        • Governance Documents
        • Committee Composition
      • Annual Reports
      • Annual Meeting and Proxy
      • Clinical Studies
      • Fact Sheet
      • SEC Filings
      • Email Notification
      • Information Request
      • FAQs
    • Contact Us
      • Contact Information
      • Contact Us Form

Cardiac Defects:

Patent Foramen Ovale (PFO)
Learn More

Artrial Septal Defect (ASD)
Learn More 

Ventricular Septal Defect (VSD)
Learn More 

NMT Medical

NMT Medical is a pioneer in the field of non-surgical repair of structural heart defects in children and adults. Over 30,000 septal defects have been closed using our proprietary technology.

Clinical Trials

Recently Completed Trials:
MIST (Migraine Intervention with STARFlex® Technology) defined the “treatment effect” of closing a patent foramen ovale (PFO) in certain patients suffering from refractory migraine headache.

BEST (BioSTAR® Evaluation Study) demonstrated closure rates for the worlds first bioabsorbable septal repair implant to be significantly better than competing technologies.

Ongoing Clinical trials:
CLOSURE I (enrollment completed) - compares current medical therapy to PFO closure in patients who have experienced a stroke or TIA.

MIST III - is a follow-on study to the completed MIST trial.

3/9/2010
NMT Medical to Release Fourth-Quarter and Year-End 2009 Financial Results on March 25

3/3/2010
NMT Medical Appoints John E. Ahern to Board of Directors

2/17/2010
NMT Medical Announces $5.8 Million Financing

2/10/2010
NMT Medical Reports Preliminary Full Year 2009 Revenues of Approximately $13.2 Million

10/29/2009
NMT Medical Announces Third-Quarter 2009 Financial Results

 

Home | About NMT Medical | Structural Heart Repair | NMT Technology | Patient Education | Medical Professionals 
Investors | Contact Us | Privacy Policy | Glossary | Login 

All content © 2009 NMT Medical, Inc.
NMT Medical, Inc., 27 Wormwood Street, Boston, MA 02210 | 617.737.0930 
Web Design and Web Development by Wakefly